18-Oct-2022 | Facts and Factors
According to Facts and Factors, the global plasmid market size was worth around USD 127.5 million in 2021 and is estimated to grow to about USD 363.9 million by 2028, with a compound annual growth rate (CAGR) of approximately 19.1% over the forecast period. The report analyzes the plasmid market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the plasmid market.
The plasmid is a genetic engineering tool that transports genetic material into human cells using genetically modified circular DNA molecules. Plasmid DNA is critical in today's healthcare industry. It can be used directly for medicinal uses, such as gene therapy and vaccine antigen manufacture, and indirectly for several research objectives, such as gene mapping and gene cloning, to help avoid disorders such as cystic fibrosis or Huntington's disease. Plasmids are important starting materials for sophisticated therapeutics like RNA vaccines and viral vectors. Inherited disorders, some viral infections, and other diseases (especially those for which there is now no cure) have all found promise in genetically engineered medicines.
Browse the full “Plasmid Market Size, Share, Growth Analysis Report By General Type (Conjugative, Non-Conjugative), By Specific Plasmid Types (F-Plasmids, Col Plasmids, Resistance Plasmids, Cryptic Plasmids, Degradative Plasmids, Virulence Plasmids), By Application (Transfection, Recombinant DNA Technology, Gene Therapy, Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/plasmid-market
A significant element driving the growth of the global plasmid market is the rise in the number of patients choosing gene therapy. A surge in the development of gene therapy has caused a sharp increase in plasmid demand. The preference for viral vectors in many therapies has increased, which has resulted in breakthroughs in plasmids. Utilizing viral vectors has several benefits, including the minimal risk of chromosomal integration, resilience due to process validations, limited infection to a wide range of cells, and simple culture production, encouraging their adoption and accelerating market expansion. Increased financing for gene therapy research & development, rising cancer rates, viral infection, genetic abnormalities, and greater public awareness of gene therapy are the main drivers for the expansion of the global plasmid market. The growth of the plasmid business is constrained by the high cost of gene therapies, the risk of mutagenesis, and other challenges in gene therapy.
The global plasmid market is segregated based on general type, specific plasmid types, application, and region. Based on general type, the market is divided into conjugative and non-conjugative. Among these, the conjugative segment dominated the market in 2021. Based on specific plasmid types, the market is divided into F-plasmids, col plasmids, resistance plasmids, cryptic plasmids, degradative plasmids, and virulence plasmids. Over the forecast period, the col plasmid segment is expected to develop significantly. Based on application, the market is classified into transfection, recombinant DNA technology, gene therapy, and others. The gene therapy segment dominated the market in 2021.
The global plasmid market is divided into geographic regions: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America dominated the global plasmid market in 2021 because of the region's robust product pipeline, high acceptability of plasmid-based therapies in the U.S., increased cancer & monogenic illnesses, and technological improvements. A sizable number of centers and institutes involved in the R&D of advanced medicines contribute to this regional market's significant share. The federal agencies' investments in the region's plasmid research base are expected to boost North America's market expansion.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 127.5 Million |
Projected Market Size in 2028 |
USD 363.9 Million |
CAGR Growth Rate |
19.1% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
VGXI Inc., Kaneka Corporation, Aldevron, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, Vigene Biosciences, Akron Biotech, Waisman Biomanufacturing, LakePharma Inc., MeiraGTx Limited, Eurofins Genomics, Biomay, Luminous BioSciences (LBS) LLC, Genscript Biotech Corporation, GENEWIZ, Creative Biogene, JAFRAL Ltd., Luina Bio Pty Ltd, Cepham Life Sciences, Lonza, Greenpak Biotech Ltd, Delphi Genetics, Biomiga, Genopis Inc., Altogen Biosystems, Puresyn Inc., GeneImmune Biotechnology Corp., Synbio Technologies, Geneone Life Science, Ajinomoto Bio-Pharma Services., and others. |
Key Segment |
By General Type, Specific Plasmid Types, Application, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Key players functioning in the global plasmid market include VGXI Inc., Kaneka Corporation, Aldevron, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, Vigene Biosciences, Akron Biotech, Waisman Biomanufacturing, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Biomay, Luminous BioSciences (LBS), LLC, Genscript Biotech Corporation, GENEWIZ, Creative Biogene, JAFRAL Ltd., Luina Bio Pty Ltd, Cepham Life Sciences, Lonza, Greenpak Biotech Ltd, Delphi Genetics, Biomiga, Genopis Inc., Altogen Biosystems, Puresyn, Inc., GeneImmune Biotechnology Corp., Synbio Technologies, Geneone Life Science, and Ajinomoto Bio-Pharma Services.
Recent developments:
- July 2021: To fulfill the rising demand for plasmid DNA-based medicines and mRNA-based vaccinations, Thermo Fisher Scientific Inc. announced the launch of a new cGMP plasmid DNA production facility in Carlsbad, California.
- April 2020: For its BioReliance virus and gene therapy service offering, Merck announced the opening of a second facility in Carlsbad, California, in the United States. The new facilities, which cost €100 million, will double the available production capacity and allow for the large-scale commercial manufacture of medicines used in gene and virus therapies.
Global plasmid market is segmented as follows:
By General Type
- Conjugative
- Non-Conjugative
By Specific Plasmid Types
- F-Plasmids
- Col Plasmids
- Resistance Plasmids
- Cryptic Plasmids
- Degradative Plasmids
- Virulence Plasmids
By Application
- Transfection
- Recombinant DNA Technology
- Gene Therapy
- Others
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
